The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.
: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage. NEWM-035
If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035 The drug was developed by , a spinoff